Diversified Trust Co Sells 20,175 Shares of DexCom, Inc. (NASDAQ:DXCM)

Diversified Trust Co trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 53.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,357 shares of the medical device company’s stock after selling 20,175 shares during the quarter. Diversified Trust Co’s holdings in DexCom were worth $1,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Nordea Investment Management AB lifted its holdings in DexCom by 2.8% in the 4th quarter. Nordea Investment Management AB now owns 80,590 shares of the medical device company’s stock worth $6,271,000 after buying an additional 2,183 shares during the period. GAMMA Investing LLC raised its holdings in shares of DexCom by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 8,258 shares of the medical device company’s stock valued at $642,000 after acquiring an additional 2,665 shares in the last quarter. Versant Capital Management Inc purchased a new stake in DexCom in the fourth quarter worth $25,000. B. Riley Wealth Advisors Inc. boosted its holdings in DexCom by 42.3% in the third quarter. B. Riley Wealth Advisors Inc. now owns 5,590 shares of the medical device company’s stock valued at $370,000 after acquiring an additional 1,662 shares in the last quarter. Finally, Tidal Investments LLC increased its position in DexCom by 68.0% during the 3rd quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company’s stock valued at $2,463,000 after purchasing an additional 14,872 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Citigroup lifted their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Royal Bank of Canada cut their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group increased their target price on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Leerink Partners dropped their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, Oppenheimer decreased their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $98.00.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 0.9 %

Shares of NASDAQ:DXCM opened at $80.09 on Thursday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market cap of $31.28 billion, a P/E ratio of 47.96, a PEG ratio of 2.46 and a beta of 1.12. The stock’s fifty day moving average price is $76.59 and its 200-day moving average price is $79.52.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.